Report of an international expanded access program of imatinib in adults with Philadelphia chromosome positive leukemias

Annals of Oncology

Volumn 19, Issue 7, 2008, Pages 1320-1326

  Capdeville, Renaud ^a   Krahnke, T ^a   Hatfield, A ^a   Ford, J M ^a   Van Hoomissen, I ^b   Gathmann, I ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b PPD Pharmaco   (Belgium)

Author keywords

Chronic myeloid leukemia (CML); Expanded access program (EAP); Glivec; Imatinib

Indexed keywords

ALPHA INTERFERON; IMATINIB;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BONE MARROW SUPPRESSION; BONE MARROW TRANSPLANTATION; BONE PAIN; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CHRONIC MYELOID LEUKEMIA; CLINICAL OBSERVATION; CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DRUG APPROVAL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FATALITY; DRUG MARKETING; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPNEA; FEBRILE NEUTROPENIA; FEMALE; FEVER; GASTROINTESTINAL HEMORRHAGE; GENERAL CONDITION DETERIORATION; HEADACHE; HEALTH CARE ACCESS; HEALTH CARE DELIVERY; HEALTH CARE SYSTEM; HEALTH PROGRAM; HEART DISEASE; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPOTENSION; INFECTION; INTERNATIONAL COOPERATION; LUNG INFILTRATE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OVERALL SURVIVAL; PHILADELPHIA 1 CHROMOSOME; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; RESPIRATORY FAILURE; RESPIRATORY TRACT DISEASE; SEPSIS; SEPTIC SHOCK; SIDE EFFECT; SUBDURAL HEMATOMA; THORAX PAIN; TIME; TREATMENT DURATION; TREATMENT OUTCOME; VOMITING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; DISEASE PROGRESSION; FEMALE; HUMANS; INTERNATIONAL COOPERATION; KAPLAN-MEIERS ESTIMATE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKEMIA, MYELOID, CHRONIC-PHASE; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; PIPERAZINES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGRAM DEVELOPMENT; PROTEIN KINASE INHIBITORS; PYRIMIDINES; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 46249089543     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn050     Document Type: Article

References (21)

1. Druker BJ, Talpaz M, Resta D et al. Clinical efficacy and safety of an ABL specific tyrosine kinase inhibitor as targeted therapy for chronic myelogenous leukemia. 41st annual meeting of the American Society of Hematology. Blood 1999; 94: Abstr 1639.
2. Druker BJ et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Eng J Med 2001; 344: 1031-1037.
3. Capdeville R, Buchdunger E, Zimmerman J, Matter A. Glivec (STI571, imatinib), a rationally developed targeted anticancer drug. Nat Rev Drug Discov 2002; 1: 493-502:
4. Kantarjian H, Sawyers C, Hochhaus A et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002; 346: 645-652.
5. Talpaz M, Silver RT, Druker BJ et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: Results of a phase 2 study. Blood 2002; 99: 1928-1937.
6. Sawyers CL, Hochhaus A, Feldman E et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: Results of a phase II study. Blood 2002; 99: 3530-3539.
7. Cohen MH, Williams G, Johnson JR et al. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res 2002; 8: 935-942.
8. Lemonick MD, Park A. New hopes for cancer. Time 28 May 2001.
9. Finkelstein JB. FDA clarifies rules for getting experimental drugs. J Natl Can Inst 2007; 99(8)): 584-589.
10. Herceptin® Lottery Ends. Trials Expand to Include More Eligible Patients http://www.nih.gov/news/pr/sept98/nci-22.htm (26 March 2007, date last accessed).
11. Bourg E, de Crémiers F. Compassionate use and early access to the market in the USA and EU. Regul Aff J 2000: 401-404. (part I)
12. Bourg E, de Crémiers F. Compassionate use and early access to the market in the USA and EU. Regul Aff J 2000: 640-645. (part II)
13. Rosti G, Martinelli G, Bassi S et al. Molecular response to imatinib in late chronic phase chronic myeloid leukemia. Biood 2004; 103: 2284-2290.
14. Ottmann OG, Druker BJ, Sawyers CL et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome positive acute lymphoid leukemias. Blood 2002; 100: 1965-1971.
15. Anonymous Amprenavir (Agenerase) now available in expanded access. AIDS Treat News 1999; (304): 5.
16. Anonymous. Efavirenz (Sustive): Oral liquid expanded access program for children and adolescents ages 3-16. AIDS Treat News 2000 342): 4.
17. Anonymous Expanded access programs. Treat Rev 1997; (26-27): 12.
18. Anonymous Tenofovir DF expanded access. Criteria for U.S. program. AIDS Treat News 2001; (360): 2-3.
19. Govindan R, Natale R, Wade J et al. Efficacy and safety of gefitinib in chemonaive patients with advanced non-small cell lung cancer treated in an Expanded Access Program. Lung Cancer 2006; 53: 331-337.
20. Obasaju CK, Ye Z, Wozniak AJ et al. Single-arm, open label study of pemetrexed plus cisplatin chemotherapy in naïve patents with malignant pleural mesothelioma: Outcomes of an expanded access program. Lung Cancer 2007; 55(2): 187-194.
21. Lassarat S, Jootar S. Ongoing challenges of a global international patient assistance program. Ann Oncol 2006; 17 (Suppl 8): Viii43-viii46.